

新規薬剤開発・評価研究部 論文(2014年)

【英語論文】

原著論文

1. Kaira K*, Serizawa M*, Koh Y, Takahashi T, Yamaguchi A, Hanaoka H, Oriuchi N, Endo M, Ohde Y, Nakajima T, Yamamoto N. Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer. *Lung Cancer*. 2014;83(2):197-204. (*共同第一著者)
2. Serizawa M, Koh Y, Kenmotsu H, Isaka M, Murakami H, Akamatsu H, Mori K, Abe M, Hayashi I, Taira T, Maniwa T, Takahashi T, Endo M, Nakajima T, Ohde Y, Yamamoto N. Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: a prospective single-institute study. *Cancer*. 2014;120(10):1471-1481.
3. Serizawa M, Murakami H, Watanabe M, Takahashi T, Yamamoto N, Koh Y. Peroxisome proliferator-activated receptor γ agonist efatutazone impairs transforming growth factor β 2-induced motility of epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer cells. *Cancer Sci*. 2014;105(6):683-689.
4. Serizawa M, Kusuhara M, Zangiacomi V, Urakami K, Watanabe M, Takahashi T, Yamaguchi K, Yamamoto N, Koh Y. Identification of metabolic signatures associated with erlotinib resistance of non-small cell lung cancer cells. *Anticancer Res*. 2014;34(6):2779-2787.